Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium
Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the associati...
Saved in:
Published in | BMC medicine Vol. 14; no. 1; p. 62 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
05.04.2016
BioMed Central |
Subjects | |
Online Access | Get full text |
ISSN | 1741-7015 1741-7015 |
DOI | 10.1186/s12916-016-0607-5 |
Cover
Loading…
Abstract | Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality.
This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs.
Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking.
This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation. |
---|---|
AbstractList | Background:
Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality.
Methods:
This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs.
Results:
Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking.
Conclusions:
This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation.
Keywords:
Smoking Cancer Incidence Mortality Cohort Meta-analysis Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality.BACKGROUNDSmoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality.This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs.METHODSThis is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs.Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking.RESULTSOverall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking.This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation.CONCLUSIONSThis investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation. Background: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. Methods: This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. Results: Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. Conclusions: This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation. Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation. Background: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. Methods : This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. Results : Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. Conclusions: This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation. |
ArticleNumber | 62 |
Audience | Academic |
Author | Nilsson, Lena Maria Bueno-de-Mesquita, Bas O’Doherty, Mark G. Hofman, Albert Ruiter, Rikje Jousilahti, Pekka Kampman, Ellen Ordóñez-Mena, José Manuel Malyutina, Sofia Orfanos, Philippos Katsoulis, Michail Orsini, Nicola Scott, Angela Freisling, Heinz Stricker, Bruno H. Söderberg, Stefan Schöttker, Ben Trichopoulou, Antonia Wilsgaard, Tom de Groot, Lisette CPGM Freedman, Neal D. Kee, Frank Tamosiunas, Abdonas Håkansson, Niclas Tjønneland, Anne Jenab, Mazda Kubínová, Růžena Brenner, Hermann Wolk, Alicja de Keyser, Catherine E. Boffetta, Paolo Mons, Ute Kuulasmaa, Kari Pająk, Andrzej Bobak, Martin |
Author_xml | – sequence: 1 givenname: José Manuel surname: Ordóñez-Mena fullname: Ordóñez-Mena, José Manuel – sequence: 2 givenname: Ben surname: Schöttker fullname: Schöttker, Ben – sequence: 3 givenname: Ute surname: Mons fullname: Mons, Ute – sequence: 4 givenname: Mazda surname: Jenab fullname: Jenab, Mazda – sequence: 5 givenname: Heinz surname: Freisling fullname: Freisling, Heinz – sequence: 6 givenname: Bas surname: Bueno-de-Mesquita fullname: Bueno-de-Mesquita, Bas – sequence: 7 givenname: Mark G. surname: O’Doherty fullname: O’Doherty, Mark G. – sequence: 8 givenname: Angela surname: Scott fullname: Scott, Angela – sequence: 9 givenname: Frank surname: Kee fullname: Kee, Frank – sequence: 10 givenname: Bruno H. surname: Stricker fullname: Stricker, Bruno H. – sequence: 11 givenname: Albert surname: Hofman fullname: Hofman, Albert – sequence: 12 givenname: Catherine E. surname: de Keyser fullname: de Keyser, Catherine E. – sequence: 13 givenname: Rikje surname: Ruiter fullname: Ruiter, Rikje – sequence: 14 givenname: Stefan surname: Söderberg fullname: Söderberg, Stefan – sequence: 15 givenname: Pekka surname: Jousilahti fullname: Jousilahti, Pekka – sequence: 16 givenname: Kari surname: Kuulasmaa fullname: Kuulasmaa, Kari – sequence: 17 givenname: Neal D. surname: Freedman fullname: Freedman, Neal D. – sequence: 18 givenname: Tom surname: Wilsgaard fullname: Wilsgaard, Tom – sequence: 19 givenname: Lisette CPGM surname: de Groot fullname: de Groot, Lisette CPGM – sequence: 20 givenname: Ellen surname: Kampman fullname: Kampman, Ellen – sequence: 21 givenname: Niclas surname: Håkansson fullname: Håkansson, Niclas – sequence: 22 givenname: Nicola surname: Orsini fullname: Orsini, Nicola – sequence: 23 givenname: Alicja surname: Wolk fullname: Wolk, Alicja – sequence: 24 givenname: Lena Maria surname: Nilsson fullname: Nilsson, Lena Maria – sequence: 25 givenname: Anne surname: Tjønneland fullname: Tjønneland, Anne – sequence: 26 givenname: Andrzej surname: Pająk fullname: Pająk, Andrzej – sequence: 27 givenname: Sofia surname: Malyutina fullname: Malyutina, Sofia – sequence: 28 givenname: Růžena surname: Kubínová fullname: Kubínová, Růžena – sequence: 29 givenname: Abdonas surname: Tamosiunas fullname: Tamosiunas, Abdonas – sequence: 30 givenname: Martin surname: Bobak fullname: Bobak, Martin – sequence: 31 givenname: Michail surname: Katsoulis fullname: Katsoulis, Michail – sequence: 32 givenname: Philippos surname: Orfanos fullname: Orfanos, Philippos – sequence: 33 givenname: Paolo surname: Boffetta fullname: Boffetta, Paolo – sequence: 34 givenname: Antonia surname: Trichopoulou fullname: Trichopoulou, Antonia – sequence: 35 givenname: Hermann surname: Brenner fullname: Brenner, Hermann |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27044418$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-120629$$DView record from Swedish Publication Index https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-422330$$DView record from Swedish Publication Index http://kipublications.ki.se/Default.aspx?queryparsed=id:133289525$$DView record from Swedish Publication Index |
BookMark | eNp9U91u0zAYjdAQ-4EH4AYsTUJckGHHTpzsAqkqgyFNIMTPreU6TvttiV1sZ9WeiNfEpiu0E0ORY-vknGP75PsOsz1jjc6ypwSfEFJXrz0pGlLlOI0K87x8kB0QzkjOMSn3ttb72aH3lxgXJefsUbZfcMwYI_VB9vPzKE2ADpQMYA2yHQoLjfxgr8DMc-m9VSCDbpGSRmmHHPgrtIKwQC7CSLbXCR-0CWipHdjWn6JBB5lLI_sbDz5ZgmnhGtpR9mgpXQAFy7gramWQqHN2QMourAt-s_30fPJxevYlwsZHHMbhcfawk73XT27no-zbu7Ov0_P84tP7D9PJRa44oSEvcS0lb2iNaVk2SmtdxmAwbqumoy2TBW9pNatnqqScFnXbzWilZ21d1AzXjWroUXa69l3JuTYxAm2EkU6BF1aC6GHmpLsRq9EJ06dpOc68KDHhBYvifC32Kx1xsXQwJHZS3kJXcaUjv8JNHfmv7uW_he8TYd1cjKNgRUEp_q_9X_owClLgqkh3ebPmR_KgWxX_kZP9jmz3i4GFmNtrweoCN2UVDZ6vDVT86wFiEtZJQTCmPL5plW7w8nYLZ3-M2gcxgFe676XRdvSCcN7ggrA6mR3foV7a0cUiSayGV5g2bIs1l70WYDobT6aSqZgwVrOywYRG1sk_WPFp9QCxaHQHEd8RvNgSLLTsw8Lbfkw173eJz7Yz-xPWpmMigW8ysd473QkF4XfvxCNAH3MRqTfFujcFTiOWoCijktxRbszv1_wCI1o9PA |
CitedBy_id | crossref_primary_10_1093_cid_ciy508 crossref_primary_10_1016_j_canep_2016_10_011 crossref_primary_10_2105_AJPH_2018_304649 crossref_primary_10_1158_1055_9965_EPI_18_1327 crossref_primary_10_3390_cancers15133422 crossref_primary_10_1002_ags3_12546 crossref_primary_10_1136_jim_2017_000413 crossref_primary_10_1016_j_pan_2017_07_001 crossref_primary_10_1111_add_15791 crossref_primary_10_1002_14651858_CD013229_pub2 crossref_primary_10_1136_bmjopen_2020_037637 crossref_primary_10_1002_sim_8458 crossref_primary_10_1016_j_eururo_2022_03_033 crossref_primary_10_1016_j_autrev_2020_102633 crossref_primary_10_1007_s40122_022_00462_1 crossref_primary_10_1016_j_pmedr_2019_100875 crossref_primary_10_1038_s41430_019_0481_2 crossref_primary_10_1002_cam4_3525 crossref_primary_10_3390_cancers11010062 crossref_primary_10_3390_ijerph19063493 crossref_primary_10_1002_14651858_CD002850_pub4 crossref_primary_10_1016_j_critrevonc_2024_104323 crossref_primary_10_3238_arztebl_2018_0571 crossref_primary_10_3389_fsurg_2019_00019 crossref_primary_10_1007_s12035_019_1591_5 crossref_primary_10_1158_1055_9965_EPI_16_0858 crossref_primary_10_1159_000530435 crossref_primary_10_1016_j_amepre_2022_07_001 crossref_primary_10_1016_j_bpg_2017_09_002 crossref_primary_10_1007_s44197_023_00144_x crossref_primary_10_1055_a_2338_3716 crossref_primary_10_18632_oncotarget_23841 crossref_primary_10_1002_pros_24646 crossref_primary_10_1097_MD_0000000000032233 crossref_primary_10_1016_j_envres_2019_108636 crossref_primary_10_6004_jnccn_2020_7657 crossref_primary_10_3390_ijerph19074084 crossref_primary_10_1038_s41598_024_56634_w crossref_primary_10_1016_j_bpg_2017_09_001 crossref_primary_10_1002_14651858_CD013229 crossref_primary_10_1002_iid3_70145 crossref_primary_10_1002_ijc_31846 crossref_primary_10_1186_s12889_019_6576_9 crossref_primary_10_1186_s12889_019_7641_0 crossref_primary_10_1186_s40959_021_00094_y crossref_primary_10_3389_fonc_2022_956451 crossref_primary_10_3389_fimmu_2022_1050876 crossref_primary_10_1080_0284186X_2021_1919756 crossref_primary_10_1016_j_ypmed_2019_03_015 crossref_primary_10_1080_0952813X_2018_1552319 crossref_primary_10_3389_fpubh_2022_780538 crossref_primary_10_1177_0391560319846012 crossref_primary_10_1136_rmdopen_2022_002874 crossref_primary_10_7759_cureus_62826 crossref_primary_10_1097_CM9_0000000000001652 crossref_primary_10_3892_wasj_2023_186 crossref_primary_10_1111_ajag_12842 crossref_primary_10_1093_annonc_mdx761 crossref_primary_10_1001_jamanetworkopen_2023_54958 crossref_primary_10_15430_JCP_2020_25_1_13 crossref_primary_10_26442_00403660_2020_02_000485 crossref_primary_10_1002_cam4_4647 crossref_primary_10_3389_fonc_2024_1499384 crossref_primary_10_3389_fonc_2020_568939 crossref_primary_10_1055_a_2338_3533 crossref_primary_10_1186_s12916_022_02417_x crossref_primary_10_3389_fonc_2021_766939 crossref_primary_10_3390_cancers14174117 crossref_primary_10_1373_jalm_2018_028613 crossref_primary_10_2188_jea_JE20220206 crossref_primary_10_1161_CIRCRESAHA_121_318051 crossref_primary_10_1016_j_euf_2018_02_007 crossref_primary_10_1016_j_ejca_2018_09_007 crossref_primary_10_3390_cancers12113320 crossref_primary_10_1136_thorax_2021_217862 crossref_primary_10_1097_MCG_0000000000000935 crossref_primary_10_1007_s10120_023_01459_1 crossref_primary_10_2147_JMDH_S479699 crossref_primary_10_1093_annonc_mdy275 crossref_primary_10_1016_j_medmic_2022_100055 crossref_primary_10_1002_cncr_34172 crossref_primary_10_7326_L20_0070 crossref_primary_10_1007_s10654_020_00640_5 crossref_primary_10_1186_s12885_020_07213_5 crossref_primary_10_4046_trd_2019_0011 crossref_primary_10_12677_ACM_2021_117420 crossref_primary_10_1016_j_prnil_2024_03_003 crossref_primary_10_1126_sciadv_abn3328 crossref_primary_10_4103_jgmh_jgmh_23_20 crossref_primary_10_5334_aogh_4572 crossref_primary_10_3390_ijerph20095740 crossref_primary_10_1186_s12931_023_02420_7 crossref_primary_10_1080_2162402X_2020_1848068 crossref_primary_10_1515_med_2024_0974 crossref_primary_10_13105_wjma_v11_i5_228 crossref_primary_10_7554_eLife_82608 crossref_primary_10_3389_fendo_2020_00066 crossref_primary_10_2196_48380 crossref_primary_10_1016_j_hoc_2023_07_005 crossref_primary_10_6004_jnccn_2019_7346 |
Cites_doi | 10.1016/j.amepre.2015.04.004 10.2105/AJPH.2008.150508 10.1016/j.ypmed.2014.05.013 10.1007/s10654-014-9977-1 10.1038/sj.bjc.6606080 10.1001/jama.2008.839 10.1038/sj.bjc.6600596 10.1186/1742-7622-10-6 10.1186/1471-2482-13-S2-S14 10.1007/s00423-007-0266-2 10.1002/ijc.23033 10.1016/j.ejca.2013.08.014 10.1016/0197-2456(86)90046-2 10.1016/j.yrtph.2013.06.001 10.1136/bmj.c221 10.1002/sim.1186 10.1002/ijc.28508 10.1007/s10552-008-9132-y 10.3399/bjgp12X636236 10.1136/bmj.327.7417.745 10.1093/aje/kwv092 10.1186/1471-2407-12-385 10.1002/ijc.24191 10.1001/jama.2013.284692 10.1136/tobaccocontrol-2012-050572 10.1002/jrsm.12 10.1136/bmj.h1551 10.1093/annonc/mdt302 10.1590/S0102-311X2010001200002 10.1002/sim.3944 10.1158/1055-9965.EPI-09-0252 10.2147/CIA.S80506 10.1093/jnci/djt023 10.1093/aje/kwr265 10.1097/00001648-199305000-00006 10.1038/bjc.2012.520 10.1001/jama.2015.3656 10.1093/oxfordjournals.aje.a116237 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2016 BioMed Central Ltd. Copyright BioMed Central 2016 info:eu-repo/semantics/openAccess Ordóñez-Mena et al. 2016 Wageningen University & Research |
Copyright_xml | – notice: COPYRIGHT 2016 BioMed Central Ltd. – notice: Copyright BioMed Central 2016 – notice: info:eu-repo/semantics/openAccess – notice: Ordóñez-Mena et al. 2016 – notice: Wageningen University & Research |
CorporateAuthor | on behalf of the Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES) Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES) |
CorporateAuthor_xml | – name: on behalf of the Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES) – name: Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES) |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 3HK 5PM ADHXS ADTPV AOWAS D8T D93 ZZAVC DF2 QVL |
DOI | 10.1186/s12916-016-0607-5 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic NORA - Norwegian Open Research Archives PubMed Central (Full Participant titles) SWEPUB Umeå universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Umeå universitet SwePub Articles full text SWEPUB Uppsala universitet NARCIS:Publications |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1741-7015 |
ExternalDocumentID | oai_library_wur_nl_wurpubs_501724 oai_swepub_ki_se_506098 oai_DiVA_org_uu_422330 oai_DiVA_org_umu_120629 PMC4820956 10037_10368 4092425761 A448459013 27044418 10_1186_s12916_016_0607_5 |
Genre | Research Support, Non-U.S. Gov't Meta-Analysis Journal Article |
GeographicLocations | Netherlands United States--US Europe |
GeographicLocations_xml | – name: Netherlands – name: United States--US – name: Europe |
GrantInformation_xml | – fundername: NIA NIH HHS grantid: R01 AG023522 – fundername: World Health Organization grantid: 001 – fundername: ; grantid: 242244 |
GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7QL 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI PRINS 7X8 -5E -5G -A0 -BR 2VQ 3HK AAPBV ABPTK ACRMQ ADINQ AFGXO C1A C24 IPNFZ N95 RIG 5PM ADHXS ADTPV AOWAS D8T D93 ZZAVC DF2 PUEGO - 5E 5G A0 ADACO BBAFP BR LI0 O0- QVL |
ID | FETCH-LOGICAL-c713t-508aa793803559ceee560700d69f3d4a27d36b8bc537328dfb36ebd8284089c93 |
IEDL.DBID | M48 |
ISSN | 1741-7015 |
IngestDate | Tue Jan 05 18:09:31 EST 2021 Mon Sep 01 03:36:40 EDT 2025 Thu Aug 21 06:55:27 EDT 2025 Thu Aug 21 06:50:55 EDT 2025 Thu Aug 21 14:11:53 EDT 2025 Sat Apr 29 05:41:37 EDT 2023 Thu Jul 10 18:59:37 EDT 2025 Sat Jul 26 02:28:47 EDT 2025 Tue Jun 17 22:07:49 EDT 2025 Tue Jun 10 21:05:47 EDT 2025 Thu May 22 21:24:07 EDT 2025 Mon Jul 21 05:51:15 EDT 2025 Thu Apr 24 22:53:29 EDT 2025 Tue Jul 01 01:14:47 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Cohort Mortality Cancer Incidence Meta-analysis Smoking |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c713t-508aa793803559ceee560700d69f3d4a27d36b8bc537328dfb36ebd8284089c93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 BMC Medicine |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12916-016-0607-5 |
PMID | 27044418 |
PQID | 1797603946 |
PQPubID | 42775 |
ParticipantIDs | wageningen_narcis_oai_library_wur_nl_wurpubs_501724 swepub_primary_oai_swepub_ki_se_506098 swepub_primary_oai_DiVA_org_uu_422330 swepub_primary_oai_DiVA_org_umu_120629 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4820956 cristin_nora_10037_10368 proquest_miscellaneous_1779021486 proquest_journals_1797603946 gale_infotracmisc_A448459013 gale_infotracacademiconefile_A448459013 gale_healthsolutions_A448459013 pubmed_primary_27044418 crossref_citationtrail_10_1186_s12916_016_0607_5 crossref_primary_10_1186_s12916_016_0607_5 |
ProviderPackageCode | CITATION AAYXX QVL |
PublicationCentury | 2000 |
PublicationDate | 2016-04-05 |
PublicationDateYYYYMMDD | 2016-04-05 |
PublicationDate_xml | – month: 04 year: 2016 text: 2016-04-05 day: 05 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC medicine |
PublicationTitleAlternate | BMC Med |
PublicationYear | 2016 |
Publisher | BioMed Central Ltd BioMed Central |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
References | R Ladeiras-Lopes (607_CR8) 2008; 19 P Boffetta (607_CR20) 2014; 29 S Gandini (607_CR7) 2008; 122 N Orsini (607_CR29) 2012; 175 L Dossus (607_CR31) 2014; 134 IR White (607_CR22) 2010; 29 JL Watters (607_CR34) 2009; 18 607_CR39 R DerSimonian (607_CR25) 1986; 7 607_CR2 C Pothirat (607_CR42) 2015; 10 L Zou (607_CR9) 2014; 50 PN Lee (607_CR4) 2012; 12 S Iodice (607_CR10) 2008; 393 A Karahalios (607_CR23) 2013; 10 IT Gram (607_CR33) 2015; 182 N Hamajima (607_CR32) 2002; 87 H Poghosyan (607_CR37) 2014; 66 M Ng (607_CR1) 2014; 311 J Peto (607_CR40) 2011; 104 H Brenner (607_CR24) 1993; 4 P Gnagnarella (607_CR35) 2013; 24 S Rohrmann (607_CR13) 2013; 108 PS Liang (607_CR5) 2009; 124 U Mons (607_CR18) 2015; 350 RD Riley (607_CR14) 2010; 340 G Naik (607_CR15) 2012; 62 J Paling (607_CR16) 2003; 327 M Huncharek (607_CR12) 2010; 100 E Botteri (607_CR6) 2008; 300 S Greenland (607_CR28) 1992; 135 LA Stewart (607_CR30) 2015; 313 V Marinho (607_CR41) 2010; 26 JS Fry (607_CR38) 2013; 67 607_CR21 M Borenstein (607_CR27) 2010; 1 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (607_CR3) 2004; 83 MM Gaudet (607_CR11) 2013; 105 JP Higgins (607_CR26) 2002; 21 G Grosso (607_CR36) 2013; 13 Suppl 2 C Gellert (607_CR17) 2013; 22 A Muezzinler (607_CR19) 2015; 49 |
References_xml | – volume: 49 start-page: e53 year: 2015 ident: 607_CR19 publication-title: Am J Prev Med doi: 10.1016/j.amepre.2015.04.004 – volume: 100 start-page: 693 year: 2010 ident: 607_CR12 publication-title: Am J Public Health doi: 10.2105/AJPH.2008.150508 – volume: 83 start-page: 1 year: 2004 ident: 607_CR3 publication-title: IARC Monogr Eval Carcinog Risks Hum – volume: 66 start-page: 12 year: 2014 ident: 607_CR37 publication-title: Prev Med doi: 10.1016/j.ypmed.2014.05.013 – volume: 29 start-page: 929 year: 2014 ident: 607_CR20 publication-title: Eur J Epidemiol doi: 10.1007/s10654-014-9977-1 – volume: 104 start-page: 389 year: 2011 ident: 607_CR40 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6606080 – volume: 300 start-page: 2765 year: 2008 ident: 607_CR6 publication-title: JAMA doi: 10.1001/jama.2008.839 – volume: 87 start-page: 1234 year: 2002 ident: 607_CR32 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6600596 – ident: 607_CR2 – volume: 10 start-page: 6 year: 2013 ident: 607_CR23 publication-title: Emerg Themes Epidemiol doi: 10.1186/1742-7622-10-6 – volume: 13 Suppl 2 start-page: S14 year: 2013 ident: 607_CR36 publication-title: BMC Surg doi: 10.1186/1471-2482-13-S2-S14 – volume: 393 start-page: 535 year: 2008 ident: 607_CR10 publication-title: Langenbecks Arch Surg doi: 10.1007/s00423-007-0266-2 – volume: 122 start-page: 155 year: 2008 ident: 607_CR7 publication-title: Int J Cancer doi: 10.1002/ijc.23033 – volume: 50 start-page: 193 year: 2014 ident: 607_CR9 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.08.014 – volume: 7 start-page: 177 year: 1986 ident: 607_CR25 publication-title: Control Clin Trials doi: 10.1016/0197-2456(86)90046-2 – volume: 67 start-page: 13 year: 2013 ident: 607_CR38 publication-title: Regul Toxicol Pharmacol doi: 10.1016/j.yrtph.2013.06.001 – volume: 340 start-page: c221 year: 2010 ident: 607_CR14 publication-title: BMJ doi: 10.1136/bmj.c221 – ident: 607_CR39 – volume: 21 start-page: 1539 year: 2002 ident: 607_CR26 publication-title: Stat Med doi: 10.1002/sim.1186 – volume: 134 start-page: 1871 year: 2014 ident: 607_CR31 publication-title: Int J Cancer doi: 10.1002/ijc.28508 – volume: 19 start-page: 689 year: 2008 ident: 607_CR8 publication-title: Cancer Causes Control doi: 10.1007/s10552-008-9132-y – volume: 62 start-page: 213 year: 2012 ident: 607_CR15 publication-title: Br J Gen Pract doi: 10.3399/bjgp12X636236 – volume: 327 start-page: 745 year: 2003 ident: 607_CR16 publication-title: BMJ doi: 10.1136/bmj.327.7417.745 – volume: 182 start-page: 917 year: 2015 ident: 607_CR33 publication-title: Am J Epidemiol doi: 10.1093/aje/kwv092 – volume: 12 start-page: 385 year: 2012 ident: 607_CR4 publication-title: BMC Cancer doi: 10.1186/1471-2407-12-385 – volume: 124 start-page: 2406 year: 2009 ident: 607_CR5 publication-title: Int J Cancer doi: 10.1002/ijc.24191 – volume: 311 start-page: 183 year: 2014 ident: 607_CR1 publication-title: JAMA doi: 10.1001/jama.2013.284692 – volume: 22 start-page: 227 year: 2013 ident: 607_CR17 publication-title: Tob Control doi: 10.1136/tobaccocontrol-2012-050572 – volume: 1 start-page: 97 year: 2010 ident: 607_CR27 publication-title: Res Synth Methods doi: 10.1002/jrsm.12 – volume: 350 start-page: h1551 year: 2015 ident: 607_CR18 publication-title: BMJ doi: 10.1136/bmj.h1551 – ident: 607_CR21 – volume: 24 start-page: 2606 year: 2013 ident: 607_CR35 publication-title: Ann Oncol doi: 10.1093/annonc/mdt302 – volume: 26 start-page: 2213 year: 2010 ident: 607_CR41 publication-title: Cad Saude Publica doi: 10.1590/S0102-311X2010001200002 – volume: 29 start-page: 2920 year: 2010 ident: 607_CR22 publication-title: Stat Med doi: 10.1002/sim.3944 – volume: 18 start-page: 2427 year: 2009 ident: 607_CR34 publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-09-0252 – volume: 10 start-page: 725 year: 2015 ident: 607_CR42 publication-title: Clin Interv Aging doi: 10.2147/CIA.S80506 – volume: 105 start-page: 515 year: 2013 ident: 607_CR11 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djt023 – volume: 175 start-page: 66 year: 2012 ident: 607_CR29 publication-title: Am J Epidemiol doi: 10.1093/aje/kwr265 – volume: 4 start-page: 229 year: 1993 ident: 607_CR24 publication-title: Epidemiology doi: 10.1097/00001648-199305000-00006 – volume: 108 start-page: 708 year: 2013 ident: 607_CR13 publication-title: Br J Cancer doi: 10.1038/bjc.2012.520 – volume: 313 start-page: 1657 year: 2015 ident: 607_CR30 publication-title: JAMA doi: 10.1001/jama.2015.3656 – volume: 135 start-page: 1301 year: 1992 ident: 607_CR28 publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a116237 |
SSID | ssj0025774 |
Score | 2.5056145 |
SecondaryResourceType | review_article |
Snippet | Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate... Background Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely... Background: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely... Background: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely... |
SourceID | wageningen swepub pubmedcentral cristin proquest gale pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 62 |
SubjectTerms | Age Aging Breast Neoplasms - epidemiology Breast Neoplasms - prevention & control Cancer Care and treatment Cohort Cohort Studies Community medicine, Social medicine: 801 Complications and side effects Confidence intervals Consortia Development and progression Exercise Female Health aspects Health sciences: 800 Helsefag: 800 Humans Incidence Lung cancer Lung Neoplasms - epidemiology Lung Neoplasms - prevention & control Male Medical disciplines: 700 Medisinske Fag: 700 Meta-analysis Mortality Netherlands Proportional Hazards Models Prospective Studies Prostate cancer Prostatic Neoplasms - epidemiology Prostatic Neoplasms - prevention & control Risk Factors Samfunnsmedisin, sosialmedisin: 801 Smoking Smoking - epidemiology Smoking - therapy Smoking cessation Smoking Cessation - statistics & numerical data VDP |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSGg8ID63wAAj8SEhWUtrx054QdVgqpCGhGCob1YSO1CxOqVptD-Jf5M7x02XCfWhbeSckya-O9_Zd78j5FUlZWbAMGZ2nFZMiEoyRF1j0hYgloVJCl-t4eyLnJ6Lz7NkFhbcmhBWudGJXlGbusQ18mNgHCVjngn5YfmHYdUo3F0NJTRuklsIXYYhXWq2dbgSsG3CTuYolccNzG0j9J_hI2PFMIOp9KLkBrPSdd18ZXK6HjgZ4EXvkP1LEH_n86GuzE-n98jdYFjSSccJ98kN6x6Q22dh6_wh-fu1zbvAID8WtK4o2H60WdS4WM7yMEzW0BIZYUUx6JziMi1FNAkaggVwMZEiOnJtmvd0Ydc5ywOuCV5y3ud30WUeIrahA8ahUsxkoViQd7VuNrc_mWJxnG_Q7Bpon7eLR-T89NP3kykLVRpYCQ7umoGFl-cg5WkMpksGc64FI0rFsZFZxY3Ix8pwWaRFmXAEBjJVwYERDHh6Ik6zMuOPyZ6rnT0kdFSogpdgUxU2E4qbPDGpzaWxiiuTljYih2G8tAMBQbxlruCbyzQi8WYAdRnQzbHIxoX2Xk4qdTf6GiPacPR1EpF3fZdlB-2xi_gFcoXuslN7taAn4N4KzN_lEXnrKVAxwJ3LPOQ3wKMhxNaA8mhACQJdDk9vOE8HhdLoLftH5GV_GntikJyzdYs0KkMIvBRoDjpG7R9srBAYcATvSQ1YuCdAmPHhGTf_5eHGBRiJ4EVH5E3H7IMuH-c_Jrpe_dTtAlHJYznOIvJ6J2GrBdikPP7_BUPTbziyGtEvM_jPfCtd2mGNrcbThoVOfdmutLvAH-jaQC-wysWT3a_xKdkfe00gWJwckb31qrXPwL5cF8-9EvkH7IR_EA priority: 102 providerName: ProQuest |
Title | Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27044418 https://www.proquest.com/docview/1797603946 https://www.proquest.com/docview/1779021486 http://hdl.handle.net/10037/10368 https://pubmed.ncbi.nlm.nih.gov/PMC4820956 https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-120629 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-422330 http://kipublications.ki.se/Default.aspx?queryparsed=id:133289525 http://www.narcis.nl/publication/RecordID/oai:library.wur.nl:wurpubs%2F501724 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1tb9MwELb2ItD4gHhfYBQj8SIhBbLasRMkhLqxqULqBIOiii9WEjtQ0SYjaTT4RfxN7hInLNPYh6ZVcpc08XP2nXN-jpAnqRChBsfYNcMgdTlPhYusa64wMZhlrP24rtYwORLjKX8_82drpC1vZR9geWFoh_WkpsXi5a-fv9-Cwb-pDT4Qr0oYs3YxLoaP8KTrr5NNGJgk2umEdy8VAJyS2xebF6ohMbBE_jSsAHIlqY0s641X53vtM8PW-ZRKSzx6jWydQseQ1SulzoxchzfIdety0lGDkZtkzWS3yNWJfal-m_z5WEVNylDdSjRPKXiFtFzmOI3uRrYBjaYJQqSgmI5OcQKXIs8EtWkEOM1IkTc51-VrujSryI0s4wmect6t_KInkc3lBgXMUKW4xoViqd5iVbaX3x9j2ZxPsDsrYf-8Wt4h08ODz_tj19ZvcBMIfVcu-H5RBPYfeODUhDAaG3CvpOdpEaZM82goNRNxECc-Q8ogncYMIKIhBuReECYhu0s2sjwz24TuxjJmCXhbsQm5ZDrydWAioY1kUgeJcci2bS-VgekgEzOTsGUicIjXNqBKLO85lt9YqDr-CYRqgKAw1w2BoHyHvOhUThrSj8uEHyEqVLNutesw1AgCX44re5lDntcSCGK4chLZlQ9wa0i-1ZPc6UmCqSf9wy3yVGspCnpUKTwWcuGQx91h1MT0uczkFcrIEMnxApC51wC1u7EW8g6RPQh3AkhA3j-Szb_XROQc3EeIrx3yrAF7T-Xd_MtI5cU3VS2Rr9wTw9AhTy8VrBQHb5V5F5_Q7voBv4xCXswQ_jP7Z10qw-pbZS1rp0DVaVWobIFfoFqCFvjr_P5_n8EDsjWs-wPuev4O2VgVlXkITucqHpB1OZMDsrl3cPTheFBP3Qzq7gW2x3tf_wLI0oZF |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF5VrQTlAXHXUOgiUZCQrDre9dpGQij0UEqbiKNFfVts7xoiGjvEsSJ-EW_8RmbstVtXKG99yCF71tfMzrGe-YaQF6kQoQLH2NZukNqcp8JG1DVb6BimZay8uOrWMByJwSn_cOadrZC_TS0MplU2OrFS1CpPcI18BwTHFw4LuXg3_WVj1yh8u9q00KjF4kj_XkDIVrw93AP-brvuwf7J7sA2XQXsBAKyuQ0eSRSBVAYOmNoQbIQGo-87jhJhyhSPXF8xEQdx4jEEslFpzODCFUQm3AnCBMGXQOWvcQahzCpZe78_-vi5DfE88KbMu9NeIHYKsKY9jNjhAyexsWYqqSZv1rGDV63BJXN4NVXTAJreIusLUDhZVYF1ySIe3CG3jStL-7Xs3SUrOrtHbgzNy_r75M-nMqpTkSru0zyl4G3SYpLj8rwdGcHQiiYoejOKae4UF4Yp4ldQk56Ay5cU8ZhzVbyhEz2P7MggqeAhx21FGZ1GJkccBmDmK8XaGYotgGfzojn97gDb8XyBzVkB28fl5AE5vRYOPiSrWZ7pDUJ7sR-zBLy4WIfcZyryVKAjobTPfBUk2iIbhl8ygymJCM_Mh28mAos4DQNlYvDUsa3HuaziqkDImvsSc-iQ-9KzyOt2yLQGE1lGvIVSIet62FYRyT4E1BwrhplFXlUUqIrgzElkKirg1hDUq0O52aEEFZJ0dzeSJ40KK-TFhLPI83Y3jsS0vEznJdL4IYLuBUDzqBbU9sZcH6EIe_Cc_I4ItwQIbN7dk41_VADnHNxSiNst8rIW9s6QvfHXvsxn32U5QRx0R7ihRbaXEpaSgxfMnP8f0Gz6Cf-0RLzNEK6ZXcwumWFXr6KiNUurclHOZHaOPzC0gFEQB_DHyx_jFrk5OBkey-PD0dETsu5WWoHbjrdJVuezUj8F73YePzMqhZJv163F_gG-jrwj |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quantification+of+the+smoking-associated+cancer+risk+with+rate+advancement+periods%3A+meta-analysis+of+individual+participant+data+from+cohorts+of+the+CHANCES+consortium&rft.jtitle=BMC+medicine&rft.au=Ord%C3%B3%C3%B1ez-Mena%2C+Jos%C3%A9+Manuel&rft.au=Sch%C3%B6ttker%2C+Ben&rft.au=Mons%2C+Ute&rft.au=Jenab%2C+Mazda&rft.date=2016-04-05&rft.eissn=1741-7015&rft.volume=14&rft.spage=62&rft_id=info:doi/10.1186%2Fs12916-016-0607-5&rft_id=info%3Apmid%2F27044418&rft.externalDocID=27044418 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon |